Some of the compounds we used to target these pathways (i.e. STF-083010 and KIRA8 against IRE1α and AEBSF against ATF6) have been extensively used in preclinical studies for neurodegenerative diseases, autoimmune diabetes, cancer and pulmonary fibrosis [46,65,89–93]. The gene discussed is ATF6; the disease is pulmonary fibrosis.